FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035732877> ?p ?o ?g. }

• W3035732877 endingPage "4928" @default.
• W3035732877 startingPage "4918" @default.
• W3035732877 abstract "Abstract Background Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival. Methods Patients treated with sorafenib for HCC from January 2008 to July 2016 in several Canadian provinces were included and retrospectively analyzed. The primary end point was overall survival (OS) of patients starting on sorafenib full dose compared to reduced dose. Secondary analysis compared OS with different mean dose‐intensity groups. Survival outcomes were assessed with Kaplan‐Meier curves and Cox proportional hazards models. A propensity score analysis was performed to account for treatment bias and confounding. Results Of 681 patients included, sorafenib was started at full dose in 289 patients (42%). Median survival for starting full and reduced dose was 9.4 months and 8.9 months ( P = .15) respectively. After propensity score matching and adjusting for potential confounders there was still no difference in survival (HR 0.8, 95% CI, 0.61‐1.06, P = .12). Almost half of the patients (45%) received a dose intensity < 50%. Median survival for mean dose intensity > 75%, 50%‐75%, and < 50% were 9.5 months, 12.9 months, and 7.1 months ( P = .005) respectively. In multivariable models, starting dose(HR 1.16, 95% CI 0.93‐1.44, P = .180) and mean dose intensity were not associated with survival. Conclusions Starting HCC patients on a reduced dose of sorafenib compared to full dose may not compromise survival. Mean dose‐intensity of sorafenib may also not affect survival." @default.
• W3035732877 created "2020-06-19" @default.
• W3035732877 creator A5007898155 @default.
• W3035732877 creator A5008282524 @default.
• W3035732877 creator A5018567739 @default.
• W3035732877 creator A5018748792 @default.
• W3035732877 creator A5038002492 @default.
• W3035732877 creator A5039850848 @default.
• W3035732877 creator A5042146146 @default.
• W3035732877 creator A5056385470 @default.
• W3035732877 creator A5068644454 @default.
• W3035732877 creator A5071666326 @default.
• W3035732877 creator A5080776657 @default.
• W3035732877 creator A5081981011 @default.
• W3035732877 creator A5083237434 @default.
• W3035732877 date "2020-06-11" @default.
• W3035732877 modified "2023-10-13" @default.
• W3035732877 title "Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database" @default.
• W3035732877 cites W1495642825 @default.
• W3035732877 cites W1600724420 @default.
• W3035732877 cites W1892405924 @default.
• W3035732877 cites W1964466002 @default.
• W3035732877 cites W1966215698 @default.
• W3035732877 cites W1971837077 @default.
• W3035732877 cites W1974342793 @default.
• W3035732877 cites W1988921429 @default.
• W3035732877 cites W1989647054 @default.
• W3035732877 cites W1994193851 @default.
• W3035732877 cites W2024450952 @default.
• W3035732877 cites W2029029081 @default.
• W3035732877 cites W2038834437 @default.
• W3035732877 cites W2076258403 @default.
• W3035732877 cites W2102942095 @default.
• W3035732877 cites W2141038754 @default.
• W3035732877 cites W2142018898 @default.
• W3035732877 cites W2159026435 @default.
• W3035732877 cites W2741672967 @default.
• W3035732877 cites W2750728943 @default.
• W3035732877 cites W2762942199 @default.
• W3035732877 cites W2787358630 @default.
• W3035732877 cites W2895926103 @default.
• W3035732877 doi "https://doi.org/10.1002/cam4.3228" @default.
• W3035732877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7367626" @default.
• W3035732877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32529797" @default.
• W3035732877 hasPublicationYear "2020" @default.
• W3035732877 type Work @default.
• W3035732877 sameAs 3035732877 @default.
• W3035732877 citedByCount "6" @default.
• W3035732877 countsByYear W30357328772021 @default.
• W3035732877 countsByYear W30357328772022 @default.
• W3035732877 crossrefType "journal-article" @default.
• W3035732877 hasAuthorship W3035732877A5007898155 @default.
• W3035732877 hasAuthorship W3035732877A5008282524 @default.
• W3035732877 hasAuthorship W3035732877A5018567739 @default.
• W3035732877 hasAuthorship W3035732877A5018748792 @default.
• W3035732877 hasAuthorship W3035732877A5038002492 @default.
• W3035732877 hasAuthorship W3035732877A5039850848 @default.
• W3035732877 hasAuthorship W3035732877A5042146146 @default.
• W3035732877 hasAuthorship W3035732877A5056385470 @default.
• W3035732877 hasAuthorship W3035732877A5068644454 @default.
• W3035732877 hasAuthorship W3035732877A5071666326 @default.
• W3035732877 hasAuthorship W3035732877A5080776657 @default.
• W3035732877 hasAuthorship W3035732877A5081981011 @default.
• W3035732877 hasAuthorship W3035732877A5083237434 @default.
• W3035732877 hasBestOaLocation W30357328771 @default.
• W3035732877 hasConcept C10515644 @default.
• W3035732877 hasConcept C126322002 @default.
• W3035732877 hasConcept C126894567 @default.
• W3035732877 hasConcept C143998085 @default.
• W3035732877 hasConcept C17923572 @default.
• W3035732877 hasConcept C203092338 @default.
• W3035732877 hasConcept C207103383 @default.
• W3035732877 hasConcept C2778019345 @default.
• W3035732877 hasConcept C2778695046 @default.
• W3035732877 hasConcept C2989005 @default.
• W3035732877 hasConcept C44249647 @default.
• W3035732877 hasConcept C50382708 @default.
• W3035732877 hasConcept C535046627 @default.
• W3035732877 hasConcept C71924100 @default.
• W3035732877 hasConcept C77350462 @default.
• W3035732877 hasConceptScore W3035732877C10515644 @default.
• W3035732877 hasConceptScore W3035732877C126322002 @default.
• W3035732877 hasConceptScore W3035732877C126894567 @default.
• W3035732877 hasConceptScore W3035732877C143998085 @default.
• W3035732877 hasConceptScore W3035732877C17923572 @default.
• W3035732877 hasConceptScore W3035732877C203092338 @default.
• W3035732877 hasConceptScore W3035732877C207103383 @default.
• W3035732877 hasConceptScore W3035732877C2778019345 @default.
• W3035732877 hasConceptScore W3035732877C2778695046 @default.
• W3035732877 hasConceptScore W3035732877C2989005 @default.
• W3035732877 hasConceptScore W3035732877C44249647 @default.
• W3035732877 hasConceptScore W3035732877C50382708 @default.
• W3035732877 hasConceptScore W3035732877C535046627 @default.
• W3035732877 hasConceptScore W3035732877C71924100 @default.
• W3035732877 hasConceptScore W3035732877C77350462 @default.
• W3035732877 hasIssue "14" @default.
• W3035732877 hasLocation W30357328771 @default.
• W3035732877 hasLocation W30357328772 @default.

• next